Stay updated on Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Sign up to get notified when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.

Latest updates to the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page
- Check7 days agoChange DetectedThe history now includes a new entry for Revision: v3.6.3 and removes the previous v3.6.2 entry, reflecting an updated software release in the page's history.SummaryDifference0.1%

- Check14 days agoChange DetectedThe page footer revision tag was updated from v3.6.0 to v3.6.2, indicating a newer version of the study record history page; this is a metadata update with no changes to the displayed study data.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRecruitment status updated to 'No longer looking for participants', indicating enrollment is closed. The history now shows Revision: v3.6.0 and removes the prior Revision: v3.5.5 entry.SummaryDifference0.2%

- Check35 days agoChange DetectedA new revision entry v3.5.5 was added to the study record history, representing an updated version of the record. The previous revision v3.5.4 remains part of the history as the prior version.SummaryDifference0.1%

- Check56 days agoChange DetectedA new revision entry v3.5.4 was added to the study record history, replacing the prior v3.5.3. This reflects an updated version of the record in the history.SummaryDifference0.1%

- Check77 days agoChange DetectedThe page reflects a change in the site/system revision label, indicating an interface or platform version update without modifying the underlying clinical trial record details.SummaryDifference0.1%

Stay in the know with updates to Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.